Massachusetts General Hospital/Dana Farber Cancer Institute — Boston, Massachusetts

Massachusetts General Hospital/Dana Farber Cancer Institute is a clinical research site located in Boston, Massachusetts, United States 02114.

Crixeo Health Trust Score: 66/100 (FAIR). This profile has not yet been claimed by the site owner.

Massachusetts General Hospital/Dana Farber Cancer Institute has participated in 3 clinical trials with 1 currently active.

Therapeutic areas: Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer.

Sponsors: A2 Biotherapeutics Inc., Sarcoma Alliance for Research through Collaboration, Emerald Clinical Inc..

Sponsor Feasibility Report

Trust Score: 66/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Massachusetts General Hospital/Dana Farber Cancer Institute?

Massachusetts General Hospital/Dana Farber Cancer Institute has a Crixeo Trust Score of 66/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Massachusetts General Hospital/Dana Farber Cancer Institute conducted?

Massachusetts General Hospital/Dana Farber Cancer Institute has 3 clinical trials on record, with 1 currently active. Their work covers Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer.

Is Massachusetts General Hospital/Dana Farber Cancer Institute accredited by Crixeo Health?

Massachusetts General Hospital/Dana Farber Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Massachusetts General Hospital/Dana Farber Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.